PointState Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-4,946,800
| Closed | -$61.5M | – | 179 |
|
|
2016
Q4 | $61.5M | Buy |
4,946,800
+1,246,800
| +34% | +$15M | 0.89% | 35 |
|
|
2016
Q3 | $50.7M | Sell |
3,700,000
-100,000
| -3% | -$1M | 0.52% | 43 |
|
|
2016
Q2 | $28.1M | Sell |
3,800,000
-900,000
| -19% | -$6.75M | 0.58% | 36 |
|
|
2016
Q1 | $30M | Buy |
4,700,000
+450,000
| +11% | +$2.52M | 0.81% | 24 |
|
|
2015
Q4 | $26.6M | Buy |
4,250,000
+750,000
| +21% | +$4.92M | 0.68% | 27 |
|
|
2015
Q3 | $20.4M | Sell |
3,500,000
-100,000
| -3% | -$770K | 0.57% | 37 |
|
|
2015
Q2 | $29.8M | Sell |
3,600,000
-900,000
| -20% | -$7.96M | 0.35% | 54 |
|
|
2015
Q1 | $37.1M | Sell |
4,500,000
-900,000
| -17% | -$6.65M | 0.5% | 46 |
|
|
2014
Q4 | $37.1M | Buy |
5,400,000
+1,650,000
| +44% | +$10.3M | 0.63% | 47 |
|
|
2014
Q3 | $20.3M | Buy |
3,750,000
+1,800,000
| +92% | +$10.5M | 0.37% | 50 |
|
|
2014
Q2 | $12.4M | Buy |
1,950,000
+1,350,000
| +225% | +$9.28M | 0.16% | 70 |
|
|
2014
Q1 | $4.84M | Sell |
600,000
-1,600,000
| -73% | -$12.5M | 0.08% | 93 |
|
|
2013
Q4 | $15M | Buy |
2,200,000
+2,000,000
| +1,000% | +$10.8M | 0.19% | 82 |
|
|
2013
Q3 | $3.68M | Buy |
+200,000
| New | +$3.88M | 0.06% | 112 |
|
Other funds holding ARIA
PointState Capital's ARIA Position: Q1 2017 in Review
PointState Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 4,946,800 shares — an estimated $61.5M sold.
PointState Capital first reported a position in ARIA in Q3 2013 and held it in 14 quarters. The position peaked at $61.5M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- PointState Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- PointState Capital sold 4,946,800 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $61.5M.
- PointState Capital first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 14 quarters.
- PointState Capital's Ariad Pharmaceuticals Inc position peaked at $61.5M in Q4 2016.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on PointState Capital's 13F filing for Q1 2017, filed 15 May 2017.